Mesoblast (ASX: MSB) — Stock Profile

About Mesoblast (ASX: MSB)

Mesoblast Limited is an Australian regenerative medicine company operating across Australia, the United States, Singapore, and Switzerland, focused on developing cell-based therapies for serious inflammatory, cardiovascular, and musculoskeletal conditions. Its proprietary technology platform is built on mesenchymal lineage cells, a specialized cell type that underpins its entire product pipeline and distinguishes its approach from conventional pharmaceutical development.

The company's lead candidate, Remestemcel-L, is in Phase III clinical trials for steroid refractory acute graft versus host disease, biologic refractory inflammatory bowel disease encompassing ulcerative colitis and Crohn's disease, chronic heart failure, and chronic low back pain due to degenerative disc disease. Mesoblast is also advancing MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. Strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal support the development and commercialization of additional candidates including MPC-150-IM, MPC-25-IC, and Ryoncil across indications ranging from pediatric graft versus host disease to wound healing and neonatal brain injury. Incorporated in 2004, the company is headquartered in Melbourne, Australia.

MFAM Research

  • [BUY] Why Mesoblast Shares (ASX MSB) Is A Speculative Stock To Buy
    August 15, 2018
    Mesoblast Limited (ASX MSB; Nasdaq MESO) is a Melbourne-based leading global stem cell company focusing on R&D in regenerative cellular medicines. The Mesoblast share price has been falling since 2011 but has since stabilised in the $1.20 to $2.00 range in the past two years. Despite the company burning piles of cash each year, investors […]
Our Exclusive Top 5 Stock Picks

Five high conviction stocks that didn't make the public list. Backed by institutional research with significant upside potential. Subscribe for free access.

Invalid email address
By subscribing, you consent to receive communications from us. You can unsubscribe at any time.

Latest Announcements

  • Mesoblast (ASX: MSB) – Phase 3 CLBP Trial Reaches 300 Patients
    July 14, 2026
    Mesoblast Limited has achieved a significant milestone in its development of a treatment for chronic low back pain, announcing that it has treated its target of 300 patients in the pivotal Phase 3 MSB-DR004 trial for rexlemestrocel-L. This enrollment target completion represents a critical inflection point for the biotech company, signaling that its confirmatory trial […]
  • Mesoblast (ASX: MSB) – Ryoncil Full Year Revenue Reaches US$115M
    July 10, 2026
    Mesoblast Limited has delivered on its commercial promise with Ryoncil generating US$115 million in net revenue for the full year 2026, exceeding the company’s initial projections. The fourth quarter alone contributed US$36 million, indicating accelerating momentum as the cellular medicine gains acceptance across pediatric centers in the United States. This financial performance represents a major […]
  • Mesoblast (ASX: MSB) – Mesoblast Draws US$50M Non-Dilutive Funding
    June 25, 2026
    Mesoblast Limited has drawn US$50 million from a five-year non-dilutive facility provided by shareholder and director Dr. Gregory George, using the proceeds to retire higher-cost debt and optimize its capital structure. The move signals confidence in the company’s commercial prospects while materially improving its financial flexibility and eliminating near-term refinancing pressure. The facility carries a […]
  • Mesoblast (ASX: MSB) – Files 2026 Quarterly Activities Report
    April 30, 2026
    Mesoblast Limited reported Ryoncil net revenues of US$30.3 million for the quarter ended March 31, 2026, with the company’s flagship product approaching US$100 million in cumulative net revenues since its launch last year. More significantly, the company achieved net operating cash spend of just US$4.1 million for the quarter, a substantial improvement driven by US$34.6 […]
  • Mesoblast (ASX: MSB) – Mesoblast Hits Patient Recruitment Target in CLBP
    April 29, 2026
    Mesoblast Limited has achieved full patient recruitment for its Phase 3 pivotal trial evaluating rexlemestrocel-L as a treatment for chronic low back pain associated with degenerative disc disease. The milestone represents a critical step toward bringing a non-opioid therapy to a massive market with significant unmet medical need. With chronic low back pain affecting more […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Biotechnology
Share This